Previous 10 | Next 10 |
home / stock / entbf / entbf news
Toronto, Ontario--(Newsfile Corp. - March 30, 2021) - Microdose Psychedelic Insights ("Microdose"), the leader in B2B psychedelic intelligence, in partnership with The Conscious Fund , the most active VC fund in the psychedelic space, is pleased to present the next edition of Psychedelic ...
Malibu, CA, United States (ABN Newswire) - Join Ellis Martin for a conversation with Timothy Ko, the CEO of Entheon Biomedical (CNSX:ENBI) (OTCMKTS:ENTBF). Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the...
Senior Pharmaceutical & Technology Executive and Current SVP, Chief Information Officer, North America at Kyowa Kirin International plc., Previously of IBM, Schering-Plough, Merck and Gilead Joins Entheon's Advisory Board Vancouver, British Columbia--(Newsfile Corp. - March 3, 2021) - ...
Completion of research and development phase for HaluGen's Psychedelics Genetic Test Vancouver, British Columbia--(Newsfile Corp. - February 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psych...
Vancouver, British Columbia--(Newsfile Corp. - February 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced ethics approval for an upcoming pre-...
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointmen...
Malibu, CA, United States (ABN Newswire) - Join Ellis Martin for a conversation with Timothy Ko, the CEO of Entheon Biomedical (CNSX:ENBI) (OTCMKTS:ENTBF). Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of...
Vancouver, British Columbia--(Newsfile Corp. - February 4, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC PINK: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment...
Vancouver, British Columbia--(Newsfile Corp. - February 2, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ( "Entheon" or the "Company" ), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides an update on licen...
KCSA Strategic Communications to Host Inaugural KCSA Psychedelics Investor Conference on January 26-27, 2021 Featuring presentations by eminent psychedelics companies and industry leaders including keynote speakers, Rick Doblin, MAPS and Amy Emerson, MAPS Public Benefit Corporat...
News, Short Squeeze, Breakout and More Instantly...
Entheon Biomedical Corp Com Company Name:
ENTBF Stock Symbol:
OTCMKTS Market:
Entheon Biomedical Corp Com Website:
2024-03-27 17:08:02 ET Addiction is an issue that affects a significant number of people worldwide. While conventional treatments have existed for decades, they offer a very low rate of efficacy, often as low as 5%. For Timothy Ko , CEO of Entheon Biomedical , the problem ...
2024-03-27 17:08:02 ET Leading-edge addiction recovery solution Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses the therapeutic potential of patient-centric psychedelic medicine to remedy the underlying causes of Substance Use Disorde...
MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”) , a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan. Dear Fel...